1. Home >
  2. Roche Acquires Disetronic Holding AG

M&A Deal Summary

Roche Acquires Disetronic Holding AG

On February 10, 2003, Roche acquired medical products company Disetronic Holding AG from Capvis

Acquisition Highlights
  • This is Roche’s 1st transaction in the Medical Products sector.
  • This is Roche’s 2nd transaction in Switzerland.

M&A Deal Summary
Date 2003-02-10
Target Disetronic Holding AG
Sector Medical Products
Buyer(s) Roche
Sellers(s) Capvis
Deal Type Add-on Acquisition

Target

Disetronic Holding AG

Burgdorf, Switzerland
Disetronic, which is based in Burgdorf near Berne, Switzerland, has been a world leader in the research and development of insulin pumps and injection systems for the treatment of diabetes since 1984.

Search 204,714 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Roche

Basel, Switzerland
Category Company
Founded 1896
Sector Life Science
Employees100,920
Revenue 60.4B CHF (2023)
DESCRIPTION
Roche's corporate headquarters in Basel, Switzerland.
Roche's corporate headquarters in Basel, Switzerland.

Roche is a research-focused healthcare company focused on pharmaceuticals and diagnostics. Roche offers differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche was founded in 1896 and is based in Basel, Switzerland.

DEAL STATS #
Overall 2 of 42
Sector (Medical Products) 1 of 5
Type (Add-on Acquisition) 2 of 35
Country (Switzerland) 2 of 3
Year (2003) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2000-06-08 Givaudan

Vernier, Switzerland

Givaudan is a provider of fragrances and flavors. Givaudan was founded in 1796 and is based in Vernier, Switzerland.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2005-07-19 GlycArt Biotechnology AG

Zurich, Switzerland

GlycArt is a Swiss biotechnology company focussed on the development and commercialisation of a new generation of antibody products based on its proprietary GlycoMAb technology. GlycArt has generated its own GlycoMAb-based antibody portfolio by in-licensing and acquiring antibodies at early stages of development and applying GlycoMAb to them.

Buy Fr.235M

Seller(S) 1

SELLER

Capvis

Baar, Switzerland

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 1990
PE ASSETS 3.9B EUR
Size Large
Type Sector Agnostic
DESCRIPTION

Capvis Equity Partners is a Swiss-based private equity firm focused on buyout, succession, and expansion investments in Switzerland, China, and Germany. Sectors of interest include Healthcare, Industrial Technology, and Advanced Services & Software. Capvis will consider both majority and minority positions. The Firm's investment horizon is four to six years. Capvis Equity Partners was formed in 1990 and is headquartered in Baar with additional offices in Germany and China.

DEAL STATS #
Overall 11 of 35
Sector (Medical Products) 1 of 2
Type (Add-on Acquisition) 3 of 16
Country (Switzerland) 5 of 17
Year (2003) 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2003-01-01 Sia Abrasives Holding AG

Charlotte, North Carolina, United States

Sia Abrasives Holding AG develops, manufactures and markets complete abrasive systems tailored to specific requirements and applications for surface preparation and finishing of all types.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2003-11-28 Gebruder Tobler AG

Urdorf, Switzerland

Gebruder Tobler AG is the Swiss wholesale distributor of heating and plumbing systems and related services.

Sell -
Mergr

Product

Company

Legal